Genzyme Shareholder Sues Over Sanofi Bid Rejection
A Genzyme Corp. investor has launched a putative class action alleging the company's rejection of Sanofi-Aventis SA's $18.5 billion offer to buy it has deprived Genzyme stockholders of the right to...To view the full article, register now.
Already a subscriber? Click here to view full article